Bristol-Myers, ImClone say FDA grants priority review of cancer drug

ImClone Systems Inc and Bristol-Myers Squibb Co said the US Food and Drug

Administration has given priority review of a supplemental biologics license application for their anti-cancer drug Erbitux.

The companies said through the application, they aim to include evidence of improved overall survival in the product's labelling in the third-line treatment of patients with metastatic colorectal cancer.

They said the FDA aims to announce the results of review in early October.

tf.TFN-Europe_newsdesk@thomson.com

wj

COPYRIGHT

Copyright AFX News Limited 2007. All rights reserved.

The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.

Neither the Subscriber nor AFX News warrants the completeness or accuracy of the Service or the suitability of the Service as a trading aid and neither accepts any liability for losses howsoever incurred. The content on this site, including news, quotes, data and other information, is provided by AFX News and its third party content providers for your personal information only, and neither AFX News nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon.
source:www.forbes.com